Technologies

Minimize

SEED Capital makes technology investments broadly within software, mobile,hardware and industrial technologies. It is often in the mix between known solutions and new technology or between known technology and new challenges that unexpected opportunities arise, and we would rather be surprised than discard solutions not within our target focus.

Abeo

Super Light Concrete Structures

Technology: 

Abeo has developed a cost-efficient concrete technology and building method consisting of a skeleton of medium to strong concrete in combination with an external layer of very light concrete.

Value Proposition: 

Abeo improves the strength of a concrete construction while cutting the overall weight in half, which lowers material costs and reduce CO2 emissions from production, transport and construction. The technology can be applied in most concrete buildings and structures.

Portfolio Manager: 
www.abeo.dk Hans Terney Rasmussen (CEO)

admaze.ly

Ad retargeting

Technology: 

Admzaly has developed an ad retargeting platform (ads targeted at people who have already visited a company's website) that is easy to use and requires no integration with the online retailer’s infrastructure. The technology analyzes the online retailer’s website and suggests relevant ads which the marketing responsible can then edit before activating and then manage much like Google Adwords.

Value Proposition: 

Online retail is booming and therefore online marketing is as well. However online retailers are faced with the issue that only 2% of visitors actually make a purchase. Marketing via retargeting is an efficient way of regaining ‘lost’ customers but current systems are expensive, complex and cumbersome, making them only relevant for very large online retailers.  

Admazely offers a simple system for all SME online retailers, that is both easy to set up and manage.

Portfolio Manager: 

Amminex ET

NOx exhaust removal from diesel vehicles

Technology: 

Amminex ET's core technology is called ASDS - Ammonia Storage and Delivery System. It allows ammonia to be safely, chemically stored in metal ammine complexes with the same volume metric capacity as pressurized liquid ammonia, which in turn can help drastically reduce NOx from the exhaust of diesel vehicles. NOx is a toxic air pollutant participating in formation of smog, ozone layer depletion and acid rain.The ASDS can also be used to supply hydrogen or ammonia to fuel cell systems.

Value Proposition: 

A number of laws have been passed both in the EU and the US, setting limits for NOx levels in exhaust. Amminex ET's solution removes NOx from exhaust accommodating these laws and greatly benefitting the environment.The possibility to use the ASDS technology to store hydrogen as ammonia also provides an opportunity to use an extremely clean, carbon-free and renewable energy source in a variety of ways.

Additional Information: 

Co-investors: Nordea-Foundation (DK), Faurecia Exhaust International (F)

Portfolio Manager: 
www.amminex.netAnnika Isaksson (CEO), Peter Terry Ward (BoD-Chairman)

ahandyhand

Peer to peer network platform

Technology: 

aHandyHand wants to systematize and categorize the market for services and tasks. aHandyHand aims at establishing themselves as the central peer to peer network platform for delivery of help and assistance with any task, for all clients, by all capable providers. 

Value Proposition: 

Private individuals and households often need help with smaller tasks such as babysitting, installing or troubleshooting new IT/technology purchases, gardening and educational assistance etc. Traditionally, individuals would recruit a person, willing and capable of completing the task, from their network of friends or family or by posting an ad on the bulletin board in the local supermarket. aHandyhand wishes to make it easier for people in need of services and people who offer services, to find each other. For providers, aHandyHand promises to turn unused time into cash and for clients, aHandyHand offers a user-friendly and manageable platform for getting tasks done.       

Portfolio Manager: 
ahandyhand.dk/Christian Arensbak

BAWAT

Treatment of ballast water

Technology: 

BAWAT has developed an easily applicable technology for de-oxidation of ballast water in ships’ ballast tanks eliminating all living microorganisms from the tanks. 

Value Proposition: 

Ballast water spreads organisms to eco systems where they are not natural inhabitants. To stop this from happening the International Maritime Organization (IMO) is in the process of passing legislation that requires ship owners to clean ballast water from virtually any living organism. BAWAT offers ship owners an effective, very price competitive and reliable solution for accommodating this legislation.BAWAT has been awarded a grant from Den Danske Maritime Fond

Portfolio Manager: 
Jan Hummer (CEO), Stig Bøgh Carlsen (CoB)

BluePrinter

Printing in 3D

Technology: 

As a common (2D) printer prints on paper a Blueprinter 'prints' 3-dimensional objects based on 3D CAD computer models.

Value Proposition: 

Blueprinter creates an easy-to-use and robust office machine that prints precise high quality models with no post processing requirements. Their offering is highly competitive compared to existing solutions.

Portfolio Manager: 

Bownty

Deal aggregator

Technology: 

Bownty is an aggregator of deals - meaning offers limited in time or numbers. They gather and sort deals from more than 100 european dealsites, which are then passed on to consumers via bownty.com and partnership sites.

Value Proposition: 

The number of dealsites has exploded over the last period making it virtually impossible for the user to maintain an overview. The consequence being that users risk missing out on the best or most relevant deals. Bownty is the answer to this concern. With Bownty users get an overview of all deals and the possibility to receive only a specific  number of deals.

Portfolio Manager: 
www.bownty.comSteffen W. Frølund

Carnad

Clean Label Stock

Technology: 

Based on a cost efficient, environmentally friendly technology using soup bones as a basis, Carnad produces high quality stock for the global food industry.

Value Proposition: 

Carnad’s products consist of pure meat containing no artificial ingredients – also known in the industry as clean label products. Clean label is increasingly in demand by consumers and therefore also by the industry.

Furthermore - due the high level of meat - the stock is rich in umami flavour and transforms the currently obtainable flat and salty taste profile into a full and rich taste profile;.

Portfolio Manager: 

Codesealer

Web banking protection services

Technology: 

Codesealer has developed a patented sealed code technology, which makes it practically impossible for cybercriminals to operate. The technology pushes out a unique and frequently changing java-applet to the user upon login making the window of opportunity for the trespasser extremely narrow.

Value Proposition: 

The banking industry loses 1 billion $ every year to cyber criminality despite spending more than 7 billion $ attempting to prevent it. Codesealer help banks to reduce losses from cybercriminals with at least 50%. Additionally Codesealer is implemented in the bank's infrastructure and is therefore invisible for the user.

Portfolio Manager: 
www.codesealer.comNikolaj Højer Nieslen (CEO)

3Dfacto

Visual configurations software

Technology: 

3Dfacto has developed a web-based application platform for visual configuration of complex products and systems - VirtuBUILD™. The solution converges logic configuration and geometric configuration into a single application platform, which can be integrated with both third party CAD packages and back office systems.

Value Proposition: 

3Dfacto helps companies optimize and manage their quotation processes efficiently from client need assessment to manufacturing by providing a solution that delivers a state-of-the-art user interface including real-time three-dimensional viewing and manipulation of the solution during configuration. The solution will help lower quotation lead-time from weeks to minutes, while saving on quotation management resources and eliminating manual errors.3Dfacto cooperates with more than 10 major companies in the manufacturing industry including ABB and Danfoss.

Portfolio Manager: 
www.3dfacto.com Thomas Randrup (CEO), Ulrik Jørring (COB)

Deskwolf

Social media marketing

Technology: 

Deskwolf offer a ”social media marketing” service to Small and mid-sized companies in the Business-to-Consumer space. Deskwolf has built a user-friendly CMS-system, that lets ordinary, non-technical users edit and manage their Facebook pages. The system allows customers to set-up and manage a series of ”apps”, for running contact forms, competitions, e-mail signup, coupon deal features, etc. on their Facebook page.

Value Proposition: 

Today, SMB’s in the Business-to-Consumer space mainly generate new business via word-of-mouth, marketing in local papers, yellow pages and websites. Facebook offers new, more cost-efficient and measurable ways to reach a specific target audience, build on-going relations with customers and potential customers and gather personal data on a target audience. For small businesses with limited sales- and marketing resources and expertise, creating and managing a professional and effective Facebook solution is complex and as technically demanding as building a website. Deskwolf’s service is a pre-packaged ”turn-key” Facebook solution, aimed at serving the needs of SMB’s.

Portfolio Manager: 
Rasmus Aaen Madsen

Endomondo

Social sportstracking community

Technology: 

Endomondo provides an online service for tracking, monitoring and coaching your physical activities such as running, biking, walking, skiing etc. It further provides an online community for sharing results and challenging friends as well as a mobile app that can track results real-time using the built-in GPS as well as coach the user with lap times and music. The app is available on all major mobile platforms.

Value Proposition: 

It is always more motivating and fun to do sports if you can track your progress and if you can do it with others to support, coach and challenge you. By providing a platform for tracking activities as well as sharing and challenging friends Endomondo help users stay motivated towards physical activities. Something of great focus in most western countries.More than 10 million people have downloaded the mobile application.

Additional Information: 

Co-investors: Several Business Angels

Portfolio Manager: 
www.endomondo.com Christian Bernitt Birk, Henrik Kølle (CoB)

Expanite

Hardening of metals

Technology: 

Expanite has developed a fast and cost-efficient process for superior surface hardening of stainless steel. The solution works by dissolving nitrogen or carbon atoms into cavities in the crystal structure of the steel.

Value Proposition: 

Stainless steel products that have been hardened by the Expanite technology has up to 100x better lifetime, they have better corrosion properties, and they are virtually impossible to scratch. Further, Expanite’s technology is not restricted by the size of the product benefitting from the hardening.Expanite is currently testing their solution with international companies.

Portfolio Manager: 
www.expanite.com Thomas Strabo Hummelshøj (CEO), Thomas Folmann (CoB)

Firmafon

Telephone solution for small and medium sized enterprises

Technology: 

Firmafon provides a telephone solution for small and medium sized enterprises. The solution works as a web-based switchboard (virtual PBX) integrated with a mobile virtual network operator (MVNO) and is executed as a simple and intuitive web based user interface (SaaS).

Value Proposition: 

Firmafon's solution provides smaller sized enterprises with telephone features that would normally only be available for larger companies. The solution is very price competitive and very user friendly.

Portfolio Manager: 
www.firmafon.dkPeter Engelbrecht (CEO), Niklas Stephenson (CTO)

Gasp Solar

Solar Cells

Technology: 

Gasp Solar has invented a technology for a high-efficiency solar cell based on standard silicon solar cells, on which nanowires made from gallium-arsenide-phosphate (GaAsP) are grown. The combination of the two materials results in a tandem junction solar cell, which means that the solar cell can transform two different parts of the sunlight’s spectre into energy.     

Value Proposition: 

The solar cell will have an energy conversion efficiency of 35% enabling effective use of solar cells on mobile devices.

 

Portfolio Manager: 

GreenGo Energy

solar panel solution

Technology: 

GreenGo Energy is an energy company offering its customers significantly lower electricity bills and a greener profile.
 

Value Proposition: 

The business model is based on a full-size service concept, where electricity is produced by solar panels placed on the customers’ roofs, while GreenGo Energy takes care of everything related to the product – installation, maintenance, and financing.  Customers are cash-positive from day 1 and are guaranteed a minimum production level for 30 years.

Focusing on large scale customers GreenGo Energy has a reference list including major property owners, housing associations and several Danish municipalities.

Portfolio Manager: 

IEV

Industrial Electrical Vehicle

Technology: 

IEV has developed an industrial electrical vehicle enabling postal services to significantly increase effectiveness of mail delivery. The vehicle will be able to service routes of 30 to 60 km and have a load capacity of 240kg.

Value Proposition: 

Postal services around the world are experiencing a steady decline in postal volume as a result of e-communication and public digitalisation. As a result of the decline in postal volume the national postal services are undergoing a major structural change requiring them to change many of the basic principles for delivering mail. The industrial electrical vehicle will enable postal services to reap significant savings on fuel and maintenance compared to the currently employed commercial gasoline fuelled scooters.

Portfolio Manager: 
Ivan Loncarevic

Leikr

Training solutions for endurance sports athletes

Technology: 

Leikr develops stylish GPS watches build on an open platform with integrated downloadable services. 

Value Proposition: 

Current GPS watch offers are limited and clunky and run on generic proprietary platforms in closed ecosystems.

At the same time on-line communities are growing at a fast pace and the most popular ones, like Endomondo, SportsTracker and TrainingPeaks, can count a consumer base of several millions.

Leikr delivers a complete training solution for the modern endurance sports athletes and amateurs. Through a  range of small, full featured, elegantly designed sports watches that are easy to operate, Leikr will deliver a personalized training experience. 

Portfolio Manager: 
www.leikr.comCristiano Cairo (CMO), Lars Møller (CTO)

Libratone

Wireless speakers

Technology: 

Libratone designs and develops wireless loudspeakers that stream music and audio wirelessly in excellent quality from which ever unit contains the user's music library (e.g. Apple iPod/iPhone/iPad, Mac or PC). Libratone speakers bring back the notion of high quality audio to the world of portable devices and adapt the audio experience to the way consumers live today.

Value Proposition: 

Libratone provides a user-friendly wireless solution with great sound quality and strong appeal to design oriented buyers. Mixing different areas of expertise, from audio technology to design, Libratone aims to bring out the best of Scandinavian design and acoustic performance.

Portfolio Manager: 
www.libratone.comTommy Andersen (CEO), Lars Andersen (CoB)

Light Extraction

LED solutions

Technology: 

Light Extraction has invented a method to grow nanostructures on LED- substrates. This is done by use of equipment, LED-manufacturers already use in their production lines. The time- and cost-efficient solution is aimed at reducing internal reflection in LEDs, which today causes 75% of the energy in high-performing LEDs to be lost as heat instead of producing light.

 

Value Proposition: 

The light efficiency of LEDs increases dramatically when the internal reflection is reduced. Consequently, it is possible to either increase the amount of light emitted from LEDs or to decrease the energy input. Furthermore, the lifetime and quality of LEDs is also improved, since heat is the most important factor determining their lifetime and performance.

Portfolio Manager: 

Nangate

Software for chip design

Technology: 

Nangate has developed a tool suite of Electronic Design Automation (EDA) software solutions, which increases the efficiency of digital Integrated Circuits (IC) to levels previously only achievable with extensive manual efforts and very large design teams.

Value Proposition: 

Nangate's tools enable custom tailoring of digital cell libraries to meet specific design targets. Cell libraries can be optimized for design goals such as power consumption, die area, operating frequency or required yield. The result: Improvements in IC performance can be achieved at much lower cost and with considerably less effort than using full-custom design methods. 

Additional Information: 

Co-investors: Sunstone Capital, Northcap Partners

Portfolio Manager: 
www.nangate.com Ole Christian Andersen (CEO)

Napatech

Network adapters

Technology: 

Napatech develops and markets advanced programmable network adapters for network traffic analysis and application off-loading. Use of FPGA technology and easy-to-use software driver interfaces allows for fast integration and an excellent migration path to Ethernet connections speeds.

Value Proposition: 

With increases in network traffic and Ethernet connectivity speeds, the capabilities of standard network monitoring systems have difficulty providing accurate and reliable measurement and analysis solutions. Napatech offers the technology that delivers hardware acceleration and server off-load increasing the OEMs' ability to maintain their competitive advantage. Napatech has customers worldwide and offices in Denmark and USA.

Additional Information: 

Co-Investors: Northzone Ventures, Ferd Venture

Portfolio Manager: 
www.napatech.com Henrik Brill Jensen (CEO), Olav Stokke (CoB)

Pion Imaging Systems

Real time grading solution

Technology: 

Pion Imaging Systems has created LiveGrader, which is a real time grading solution to be used for grading live broadcast productions on TV and Web. The unique advantages of LiveGrader are all linked to very common, technical problems related to live studio or live on-location broadcasts. LiveGrader can adjust color balance, shadows, exposure level, sharpness, noise, aliasing, color saturation, contrast and more. 

Value Proposition: 

Live Grader can as the only product in the world correct, grade and improve Live TV productions while they are produced. Today, all TV Productions, with the exception of direct TV on location, are corrected, graded and improved postproduction.

Pion Imaging Systems’ LiveGrader now gives the same options for Live TV in real time. 

Portfolio Manager: 
Kenneth Tang Lærke

Roozz

‘Software to cloud’ conversion

Technology: 

Roozz.com has developed a technology that can convert the vast majority of existing software applications and PC games to run directly in the browser without getting access to source code.

Value Proposition: 

The global market for software is experiencing a disruptive change from packaged software towards cloud based software (software available via the web). This leaves a vast catalogue of already released software almost obsolete. Roozz offers to convert the stand-alone software application to a cloud-based solution in a quick and seamless fashion and to charge for the use of the software in a variety of ways on behalf of the software owner.More than 150 applications have already been Roozzified.

Portfolio Manager: 
www.roozz.com Thomas Jam Pedersen (CEO)

Sensorist

wireless sensor system

Technology: 

Sensorist is a range of small wireless sensors collecting measurement data about your environment. The measurement data is transferred to the Cloud and the user can then access it via an App or an Internet browser.

Value Proposition: 

The sensor system allows users to measure the things they care about in and around their private homes or businesses. Real-time and historic measurement data can be visualized and explored in a user-friendly way on-the-go and the user can e.g. receive alerts when something unexpected is happening. Sensorist’s first solution is a wine cellar application, which allows users to track temperature and humidity development, to use automated surveillance service to protect wines and to estimate maturity of wines.

Portfolio Manager: 

SiOx

Metal coating

Technology: 

SiOx has invented a technology that can combine the properties of glass and metals by applying a thin film layer of glass on metal surfaces. This technology combines the desirable inert properties of glass with the desirable ductile properties of metals resulting in a corrosion resistant material. The technology can successfully be applied to all applications where corrosion protection is necessary. Initially, SiOx will focus on the market for heat exchangers.

Value Proposition: 

The technology allows for the manufacturers to produce metal that has high strength and is easy to handle, while also being corrosion resistant and having a low drag coefficient. This will enable manufacturers to substitute expensive corrosion resistant metals with cheaper corrosive metals.

Today, heat exchangers are made with stainless steel or titanium. SiOx’ technology lets manufacturers replace these materials with aluminium, which is four times cheaper than stainless steel and has a heat conductivity, which is ten times higher. The technology can therefore drastically lower the production  costs for heat exchangers.

Portfolio Manager: 
Søren Svanebjerg

Sproom

Business network for electronic document exchange (EDI)

Technology: 

Sproom is a business network, bringing together electronic structured exchange (EDI) of orders, invoices, notices, etc. between buyers and suppliers. The technology brings together the many different national and international carrier networks into one large network and is in contrast to other solutions able to 'translate' an invoice, depending on the recipient's specific requirements.

Value Proposition: 

EDI has for a while been solely for large organizations, since purchasing the solutions are both expensive and complex. For small and medium enterprises the potential savings in time and money do not match the costs, and therefore EDI solutions only reach approx. 20% of their customer's supplier-network. Customers do not get full value of their investment because they cannot switch exclusively to digital processes - and the operators have only half the potential traffic. Sproom makes EDI available to all types of businesses by establishing an exchange platform that binds a global business network together, removing barriers for sending and receiving business data electronically. It gives small businesses access to a fully digitized EDI system with improved cash flow management and traceability to follow and provides larger organizations with full value for their dearly purchased EDI solutions, which now cover all their partners.

Additional Information: 

Co-investors: Accelerace Invest

Portfolio Manager: 
www.sproom.dk Steen Haustrup (CEO)

StoryPlanet

Interactive multimedia storytelling

Technology: 

StoryPlanet is a platform that is able to support practically any kind of interactive story and work across channels (mobile, desktop and cloud). The platform allows the user to specify how multimedia content such as photos and video along with story apps, themes and effects should behave in a story. The platform is device agnostic and requires no programming skills to use.

Value Proposition: 

The market for storytelling is enormous considering the amount of linear single-media content generated online at sites like YouTube, Flickr and Blogger. However current tools for interactive multimedia storytelling requires users to obtain or buy significant programming skills. StoryPlanet offers a free platform that allows non-technical users to produce and share stories.

Additional Information: 

Co-investors: various business angels

Portfolio Manager: 

Trustpilot

Online reputation management

Technology: 

Trustpilot is a web portal where consumers rank companies based on their customer service. Besides ratings done via www.trustpilot.com rankings of companies is gathered through information from governmental sources, consumer organizations, media coverage and all ratings and customer reviews on shopping portals, price comparison sites, blog discussions etc.

Value Proposition: 

The Trustpilot service facilitates the trust building process between vendor and consumer, which creates a more comfortable environment for consumers to shop in. Trustpilot offers vendors a partnership package which they can use to actively work with Trustpilot as part of their website and sales cycle.

Portfolio Manager: 
www.trustpilot.dk Peter Holten Mühlmann (CEO)

Vivino

Wine app

Technology: 

Vivino is a mobile app which can recognize wine labels via image recognition among millions of existing wines on the market. It provides an easy and fun way of rating and storing wine experiences – and sharing these with friends.

Value Proposition: 

Most wine consumers have found themselves at a dinner party or in a restaurant drinking a wine that they really like - and would like to buy for future consumption, but rarely has this resulted in an actual purchase. This is partly due to a very fragmented market with a huge number of producers and a very large number of importers, distributors and vendors.

Vivino bridges the gap between tasting a great wine and buying it - when the impulse to buy is strongest.

Portfolio Manager: 
www.vivino.comHeini Zachariassen (CEO), Niels Vejrup Carlsen (CoB)

Wantr

Social Shopping Community

Technology: 

Wantr has created a social shopping community offering consumers a coherent shopping experience that simplifies product discovery and expedites decision-making. Wantr is a platform for sharing interesting products ranging from design and apparel to gadgets and home décor. Users not only post interesting buys, but also where the item can be found and at what price.

Value Proposition: 

Wantr offers a solution that combines the discovery and sharing experience with the transparency of price comparison. Wantr offers their users a place where they can get together with other people, who are passionate about the same kinds of products as them, and in unison find the best place to buy them. 

Portfolio Manager: 

watAgame

Social network gaming

Technology: 

watAgame produces, publishes and operates the social network game goSupermodel - a fashion themed game that allows its users to style their own model character. Characters can interact with their peers in the virtual fashion community, attend photo-shoots, dance competitions, design their own clothing lines and make new friends. WatAgame uses moderators and a sophisticated safety software system to ensure a safe and wholesome experience for the users.

Value Proposition: 

goSupermodel is aimed at 10-16 year old girls and the key focus is personal expression, creativity and imagination. By earning (playing) or purchasing points the girls can add features, clothes, etc to their online avatar. Additionally watAgame's revenue is based on advertising.5 million unique visitors visit goSupermodel every month from 8 different countries.

Additional Information: 

Co-investors: Vækstfonden, Accel Partners

Portfolio Manager: 
www.gosupermodel.comwww.watagame.comHenrik Riis (CEO), Kevin Earle Comolli (CoB)

Windar Photonics

Wind turbine optimisation

Technology: 

Windar Photonics has developed a sensor that measures the wind's direction and speed up to 100 meters ahead of the wind turbine. This gives the turbine time to adjust its position and angles of its wings in due time to be optimised for changing wind conditions.

Value Proposition: 

Windar Photonic's solution provides wind turbine owners and manufacturers with a 3-5% increase in power production as well as a 10% less stress on the vital components of the wind turbine.  

Additional Information: 

Co-investors: Several business angels

Portfolio Manager: 

Medtech

Minimize

Denmark is a significant hotspot for medical tehnologies with top level research institutions and several major pharmaceutical companies. It is SEED Capitals intent to seek out companies that can build upon or utilize the unique competencies within the Danish ecosystem.

Acarix

Diagnostics of artery constrictions

Technology: 

Acarix is developing a product, which, by listening to the passage of blood through the arteries surrounding the heart will give an indication of whether a patient has stenosis, which can lead to a heart attack. The product is an advanced microphone attached to the patient's chest that within three minutes is able to assess whether the blood passage through the arteries is so turbulent that there is a need to investigate further.

Value Proposition: 

In the western world heart attacks is the most common cause of death, and for a quarter of incidents this happens entirely without warning. Acarix will save lives by - as part of the general practitioners investigation - discovering which patients need further examinations. In addition, every second of the current used costly cardiac examinations shows that the patient does not require treatment. Acarix will spare patients of being subjected to unnecessary invasive radiological studies and will also help health practitioners target when to use the more extensive examinations.

Additional Information: 

Co-Investors: Coloplast, Seventure, Sunstone Capital

Portfolio Manager: 
www.acarix.com Peter Samuelsen (CEO)

Acesion Pharma

Treatment of atrial fibrillation

Technology: 

Acesion Pharma is developing more efficacious and safer dugs for the treatment of atrial fibrillation (AF). The scientific target is the so-called SK channels, an ion channel which is also present in the heart where it is relevant for the regulation of the cardiac rhythm. Acesion Pharma have shown that inhibition of SK channels both protects against induction of AF and reverts sustained AF with efficacy comparable to the gold standard amiodarone.

Value Proposition: 

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and it mainly affects the elderly population. AF often causes an pronounced decrease in quality of life and furthermore increases the risk of stroke. Existing drug therapies only have a limited effect and produces risks of serious adverse events. Therefore, there is a considerable need for developing better and safer drugs. Inhibition of SK channels constitute a novel and promising drug target for the treatment of AF, and Acesion Pharma aims to develop a first-in-class SK inhibitor for the acute cardioversion of AF.

Additional Information: 

Co-Investors: Novo Seeds

Portfolio Manager: 
www.acesionpharma.comUlrik S. Sørensen (CEO), Morten Grunnet (CSO)

Alkalon

Medicated chewing gum

Technology: 

Alkalon is engaged in formulation development and supply of over-the-counter medical products. The company's primary focus is a portfolio of new, improved nicotine gum formulations, with a crunchy coating and the same release of nicotine as reference product Nicorette®.

Value Proposition: 

Alkalon operates in the middle of the pharmaceutical value chain offering contract development of finished product formulations. They are able to provide pharmaceutical companies with medicated chewing gum in various flavours via a reliable supply chain with high production capacity and competitive prices.Alkalon is interested in strategic partnerships and supply agreements with well-known pharmaceutical companies in Europe and elsewhere.

Portfolio Manager: 
www.alkalon.com Bo Tandrup (CEO), Pal Helmich (COB)

Aros Pharma

Irritable Bowel Syndrome pain treatment

Technology: 

Aros Pharma is developing a new effective therapy reducing the pain associated with Irritable Bowel Syndrome (IBS). The company has acquired all rights to a new chemical entity that can negatively modulate the activity of acid sensors in the gastrointestinal tract. These acid sensors are believed to play a central role in pain associated with IBS.

Value Proposition: 

Although not life threatening, IBS can seriously impair overall quality of life, and as a result it is one of the most common reasons for visits to primary care physicians and gastroenterologists.

Additional Information: 

Co-investors: Novo Seeds

Portfolio Manager: 

Asante

Disposable drug delivery system

Technology: 

Asante Solutions Inc. (former M2 Medical) has developed a small, disposable insulin pump.

Value Proposition: 

The pump is targeted towards T1 diabetics. It is easy to use, affordable and reliable and it has very strong appeal to patients.Asante received 510K regulatory approvals in USA and expect a commercial launch in 2013.

Additional Information: 

Co-investors: Sunstone Capital, Novo Ventures, Denovo Ventures, LFI Life Science Investments and Thomas, McNerney & Partners

Portfolio Manager: 
www.asantesolutions.comDavid Thrower (CEO), Pete McNerney (Chairman)

Concit Pharma

Drugs for removing movement disorders

Technology: 

Concit Pharma develops new drugs by combining safe and well-documented substances in a unique way.

Value Proposition: 

Parkinson's disease and Schizophrenia are today treated with drugs that - to some extent - are able to eliminate the disease symptoms, but in turn result in highly annoying involuntary movements. These adverse effects, for which there is no good treatment, significantly reduce quality of life and can be so massive that the diseases cannot be optimally treated. Concit Pharma drugs will ameliorate movement disorders including those associated with treatment of Parkinson’s disease and Schizophrenia.

Portfolio Manager: 
www.concitpharma.com Sissel Vorstrup (COB), John Bondo Hansen (CEO), Mikael Thomsen (CSO)

Conrig Pharma

Treatment of atopical dermatitis

Technology: 

Conrig Pharma will reposition drug molecules with attractive safety and efficacy profiles through simple modifications and reformulations to provide fast development of new treatments of illnesses. Initial focus will be on a development of a new drug for oral treatment of atopic dermatitis (a type of eczema).

Value Proposition: 

Current oral treatments of atopic dermatitis are inefficient and there is little innovation towards new treatments. Conrig Pharma aim to develop a new safe and effective agent for this growing market.

Portfolio Manager: 
www.conrigpharma.com Sissel Vorstrup (COB), John Bondo Hansen (CEO), Mikael Thomsen (CSO)

Dep-Xplora

Prodrugs for pain relief

Technology: 

Dep-Xplora has invented novel prodrugs of clinically used NSAIDs (non-steroidal anti-inflammatory drugs) to be used in the development of depots for joint injection . Oral  NSAIDs are widely used as rescue medicine to relieve moderate to severe postoperative pain after minor joint surgery  and to alleviate inflammatory pain associated with various arthritis conditions. After injection into a joint such as the knee, the Dep-Xplora prodrug forms a depot at the site of action from which the active NSAID is released over a time period, e.g. 4-10 days.

Value Proposition: 

Dep-Xplora’s mission is to provide superior pain relief of joint associated pain based on peripheral sustained NSAID action after joint injection. By using this delivery concept, the pharmacologically effective concentration of the NSAID can be reached using less than 0.04% of the dose needed to obtain the target site after oral administration. The prodrug approach taken enables establishment of high drug concentration to manage pain and inflammation at the site of action and at the same time minimizes the risk of systemic adverse events.

Portfolio Manager: 

Diet4Life

Protein Hydrolysates

Technology: 

Diet4life are working towards verifying whether protein hydrolysates have superior weight management abilities. Diet4life’s mission is to evaluate the long-term effects of regular protein intake in conjunction with certain food products and the suitability for being a dietary supplement. 

Value Proposition: 

Lifestyle related diseases such as diabetes and obesity pose an increasing challenge to humanity and the health care systems in most parts of the developed world. A common problem with protein hydrolysates and their incorporation into food products is their pronounced bitter taste. The value proposition of Diet4life relates to the use of non-bitter protein hydrolysates in diets to reduce fat accumulation and, possibly, induce weight loss in the human body. 

Portfolio Manager: 

EpiTherapeutics

Cancer treatment in the field of epigenetics

Technology: 

EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen.Epitherapeutics is currently building a strong IPR platform based on proprietary knowledge within histone demethylases and methyltransferases and via in-house drug discovery efforts to identify small molecule inhibitors of key enzymes within the family targeting unmet medical needs.

Value Proposition: 

The development of so-called epigenetic drugs is regarded as an important point of intervention for the treatment of cancer. The scientific discoveries of EpiTherapeutics have potential applications in a wide range of clinical indications, but the company's initial focus will be on prostate cancer.

Additional Information: 

Co-investors: Novo, The Lundbeck Foundation, OSI Pharmaceuticals, Merck Serono Ventures 

Portfolio Manager: 
www.epitherapeutics.dk Martin Bonde (CEO), Peter Høngaard Andersen (CoB)

Evolva

Drug candidates based on natural products

Technology: 

Evolva develops novel genetic pathways leading to new drug candidates for the Healthcare industry. The patented Watchmaker® technology captures nature’s genetic chemistry pool and combines it with an evolutionary process leading to discovery and optimization of novel small molecules for therapeutic targets.

Value Proposition: 

The pharmaceutical industry has largely stopped exploring conventional natural products. Natural structures are typically difficult to source, difficult to identify, difficult to analog and difficult to manufacture. However, Nature is still the most efficient supplier of long lasting healthcare ingredients. Evolva´s Watchmaker® technology creates new combinations of synthetic structured products leading to new compounds that interact with the most productive functionalities of natural products. By mixing millions of genes from multiple species such as sponges, humans & plants, Watchmaker® creates long lasting solutions for patients with lifelong conditions.Evolva is listed on the Swiss Stock Exchange as Evolva Holding SA.

Portfolio Manager: 
www.evolvabio.comNeil Goldsmith (CEO), Prof. Dr. Erich Schlick (CoB)

Galecto Biotech

Treatment of IPF

Technology: 

Galecto Biotech develops a novel drug for the deadly lung disease called Idiopathic Pulmonary Fibrosis (IPF). IPF is an orphan decease affecting about 30.000 Americans every year.

Value Proposition: 

IPF is characterised by a condition in which over a period of time the lung tissue becomes thickened, stiff, and scarred.  As a result, the brain and other organs don't get the oxygen they need with fatal consequences. There is currently no cure for this decease.

Additional Information: 

Co-Investors: Novo Seeds, MerckSerono Ventures and Sunstone Capital

Portfolio Manager: 
www.galecto.comHans Schambye (CEO)

Glycom

Novel biomolecules for the pharmaceutical and food industries

Technology: 

Glycom's principal activity is to develop and sell new biomolecules to the food ingredient industry. The company has unique know-how and abilities within carbohydrate chemistry, which it utilizes for the development of industrial scale production of Human Milk Oligosaccharides (HMOs). HMOs are high value ingredients in infant formula and potentially other functional food products. Glycom is presently developing, in its own laboratories, synthetic processes for the preparation of selected HMOs, which are suitable for multi-ton scale production.

Value Proposition: 

HMOs are not found in cow milk and therefore currently not available in infant formulas. HMOs are documented to have prebiotic effects (nutrition for healthy intestinal bacteria) and to have important antibacterial/antiviral effects as well as stimulating early brain development on infants. Glycoms ability to synthetically produce HMO at a reasonable price will allow producers of - in particular - infant formula to offer their products with HMO.Glycom has a long-term cooperation agreement and partnership with Nestlé Nutrition and has initiated a second wave of HMO development and pre-industrialization in the beginning of 2010.

Additional Information: 

Co-investors: Private

Portfolio Manager: 
www.glycom.dk John Theroux (CEO), Kim Bøtkjær (COB), Gyula Dekany (CSO)

Intomics

Biological data analysis

Technology: 

Intomics is a contract research company with leading expertise in biological data analysis and mining, bioinformatics and systems biology. Their services include data mining and data combination, network analysis, target prioritization, text mining, and core bioinformatics services. The analyses are unique and customized to the individual project.

Value Proposition: 

Based on their proprietary tools, unique knowledge, and ability to customize solutions to meet the need of each client, Intomics can improve biological and clinical research in areas such as biomarker discovery and optimization, extraction of biological knowledge from data, drug discovery and translational research. The advanced data analyses will enable the pharmaceutical industry to get the most out of trials and research in new drug candidate, so as to discover drug and diagnostic targets cheaper and faster.In a ten-year perspective, integrative approaches like Intomics will form the basis for advanced, quantitative and qualitative types of systems biology, where simulation and modelling will be a key for the understanding of complex diseases and their underlying causes at the molecular level.In 2010 Intomics entered into collaboration with Danish pharmaceutical company Leo Pharma. 

Portfolio Manager: 
www.intomics.comThomas Skøt Jensen (CEO)

Levoss

Nano-material for treating musculoskeletal conditions

Technology: 

LevOss is developing a biodegradable material (polymer) embedded with a Nano mesh, that will be able to fit into a bone fracture or void site. The material provides mechanical stability equivalent to the native tissue and provides an environment optimized for stem cell guidance and thereby new tissue generation.

Value Proposition: 

Musculoskeletal conditions are the most common causes of severe long-term pain and physical disability, affecting hundreds of millions of people across the world. The condition is increasingly treated by transplanting synthetic solutions that however does not adhere to the bone sufficiently well.
LevOss will be able to deliver a transplant material that integrates more effectively with the bone while also providing conditions for new tissue generation.

Portfolio Manager: 
www.levoss.comMai-Britt Zocca (Interim CEO)

Medichanical Engineering

Device for hip-replacement surgery

Technology: 

Medichanical Engineering is developing the X-pander. A mechanical measuring device that will help hip-replacement surgeons objectify the needed level of component size and whether the damaged bone has been sufficiently reamed.

Value Proposition: 

The increasingly popular press-fitting technique for hip-replacements demands very precise manual surgeon skills. Both in regards to the size of the needed prosthetic component as well as whether the component will fit into the pelvic bone. If these estimates are not done correctly additional surgery is a risk resulting in added cost as well as discomfort for the patient. The X-Pander will with a few minutes use help decrease these cases with at least 50%.

Portfolio Manager: 
www.medichanical.comEske Winther Petersen (CEO)

Minervax

Vaccine against GBS infections

Technology: 

Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.

Value Proposition: 

GBS is the leading cause of life-threatening bacterial infections in newborn babies and GBS has recently been reported to cause an increasing number of serious infections in the adult population. The National Institute of Health of the US has identified prevention of GBS in newborns as a major vaccine objective, but so far no approved or universally useful vaccine exists. A general vaccine effective against relevant strains of GBS is poised to have great impact and could potentially be administered to pregnant women or women considering pregnancy as part of a general vaccine program.

Portfolio Manager: 

Mirrx Therapeutics

MicroRNA blocking technology

Technology: 

MicroRNAs are powerful cellular regulators that play a role in most cellular processes. Mirrx Therapeutics holds fundamental IP to so-called blockmirs that are capable of blocking single microRNA-mRNA interactions, i.e. capable of preventing a microRNA from regulating one particular mRNA, while still allowing the microRNA to regulate all its other mRNA targets.

Value Proposition: 

The blockmir compounds being developed by Mirrx have relevance for all major disease areas and reduce the risk of unwanted side-effects dramatically, as compared to other compounds interfering with microRNA pathways. From the number of human genes estimated to be subject to microRNA-based regulation, approximately every third human gene may be targeted by a blockmir. In addition to the apparent applications as therapeutics, blockmirs will prove highly important research tools, pivotal to the understanding of microRNA based regulatory pathways and the contributions of single microRNA-mRNA interactions.

Additional Information: 

Co-investors: Inventure Capital, Vecata Invest

Portfolio Manager: 
www.mirrx.dkThorleif Møller (CEO)

Motility Count

Disposable sperm test

Technology: 

Motility Count is developing a single-use sperm quality checker, which measures both the quality and quantity of the semen within 30 minutes.

Value Proposition: 

16% of all couples in the developed world that whishes to get pregnant have to seek assistance at In Vitro Fertilization. Half is linked to sperm quality. The Motility Count product will increase the privacy for these couples by eliminating the need to visit IVF specialist/hospital for (initial) testing of sperm.

Motility Count was awarded the Invention of The Year at the 2011 Scandinavian Industry Expo (HI11)

Additional Information: 

Coinvestors: Several business angels

Portfolio Manager: 

Nanovi

Cancer treatment

Technology: 

Nanovi has developed a new, patented product - NanoGel. NanoGel improves precision in radiotherapy treatment for cancer patients and can be used in the treatment of several types of cancer, including lung cancer. NanoGel is a goal-coated liquid marker, which is to be injected directly into the tumour for greater precision.

Value Proposition: 

Cancer is a leading cause of death worldwide and poses severe problems for humanity. More than 50% of all cancer patients receive radiotherapy at least once during their illness trajectories. NanoGel greatly improves the precision of radiation therapy without compulsory changes in current routines and equipment. The more precise treatment of cancer cells prevents unnecessary damage to healthy tissue.

Portfolio Manager: 
www.nanovi.dk/Morten Albrechtsen

Observe Medical

Digital Urine Meter

Technology: 

Observe Medical has developed a revolutionary digital urine meter - Sippi. Sippi is an easy-to-use application that monitors urine production via a bag application connected to a piece of software. Sippi is fully automatic during the length of the treatment.

Value Proposition: 

Urin production can be used as a diagnostic tool in the care of patients. However it is normally done manually by nursing staff that collect and journalize the output. Sippi's automatic abilities and data analysing software will allow staff to focus on evaluating data output and patient care, as well as reducing human errors.

Additional Information: 

Co-investors: Sahlgrenska Science Park, M2 Capital Management, Porter & Partners, Lavin Capital  

Oracain

Pain relieve for oral mucositis

Technology: 

Oracain is developing a novel pharmaceutical product for pain associated with oral mucositis and other complex conditions.

Value Proposition: 

Oral mucositis is an adverse effect of cancer chemo- or radiotherapy, where the mucosal lining of the mouth becomes thin, may slough off and then become red, inflamed and ulcerated. The condition is very painful and will often result in patients having trouble speaking, eating, or even opening the mouth. Oral mucositis is the most common distressing and disabling acute complication of cancer chemotherapy and radiotherapy as reported by patients, and is a significant dose-limiting toxicity of cancer therapy. Pain and secondary infections associated with untreated oral mucositis result in substantial increases in hospitalization costs. Development of a new pain relief product for these patients will have a significant impact on quality of life and on the cost of care for cancer patients.

Portfolio Manager: 
www.oracain.comBetina Thorball (CEO), Dr. Ove Andersen (CoB)

Reapplix

Improvements in wound healing

Technology: 

Reapplix offers a novel mechanism to enhance the inherent wound healing capability of the body - the LeucoPatch™. The LeucoPatch™ is made entirely from the patient's own blood without any additives and is therefore fully autologous and biocompatible.

Value Proposition: 

Reapplix' objective is to enable patients to benefit from the wound-healing properties of their own growth promoting factors and thereby provide a treatment option to avoid traumatic amputation surgery. Leucopatch™ increases the healing rate of chronically hard to heal and debilitating wounds thus resulting in increased quality of life for the patient and considerably lower costs for the society. Initially efforts focus on non-healing diabetic foot ulcers.Clinical trials have shown impressive results.

Additional Information: 

Co-investors: Accelerace Invest

Portfolio Manager: 
www.reapplix.comNiels Erik Holm (CEO), Bo Jesper Hansen (CoB)

Sense

Blood Pressure Sensor

Technology: 

Sense is developing novel methods for cardiovascular sensing and in particular blood pressure and vascular compliance. The technology is a small patch with a sensor that is placed directly on the patient's wrist artery. The patented sensing scheme is based on a concept that does not interfere with the physical or psychological state of the patient, which is in contrast to existing blood pressure measuring methods. It is thus very suitable for continuous ambulatory measurements.

Value Proposition: 

The Sense technology creates new possibilities for easy, comfortable, precise and continuous measurements of blood pressure. Unlike traditional inflatable cuff alternatives the technology enables patients to be monitored in natural situations with negligible discomfort.

Additional Information: 

Co-Investors: Vækstfonden

Portfolio Manager: 
www.sense-as.dk Peter M. Eriksen (CEO), Lars Lading (CSO), Kurt Erling Brik (CoB)

TagAway Devices

Health care

Technology: 

TagAway Devices ApS has granted an exclusive license to a large international consumer health care company for its patented technology.

Portfolio Manager: 
Carsten Fredsbo (CEO)

Valderm

New dermatologic treatment for psoriasis

Technology: 

Valderm is developing Valrubicin - a daily treatment of hyper proliferative skin diseases e.g. psoriasis.

Value Proposition: 

Presently, there is no permanent cure for psoriasis, but a wide range of topical, systemic, and recently biological treatments are available for the management of the condition. Valrubicin is a much-needed product for patients who will not benefit from strong therapy and who do not benefit from other milder therapies available on the market.Valderm's product has made clinical proof-of-concept in terms of antiproliferative effects. Currently Valrubicin is in clinical trials phase I/IIa.

Additional Information: 

Co-investors: FIH Partners

Portfolio Manager: 
www.valderm.dk Elisabeth de Darko (CEO)

Victorious Medical Systems

Device for cancer diagnostics

Technology: 

Victorious Medical Systems is developing a device used in cancer diagnostics.

Value Proposition: 

The device will help increase productivity and reduce hands-on procedures in a user-friendly way.

Portfolio Manager: 

Exits

SEED Capital has exited a number of interesting companies to global corporations, business angels and management buyouts.

Minimize

Fullrate

Fullrate was bought by TDC March 2009

Evolva

Drug candidates based on natural products

Technology: 

Evolva develops novel genetic pathways leading to new drug candidates for the Healthcare industry. The patented Watchmaker® technology captures nature’s genetic chemistry pool and combines it with an evolutionary process leading to discovery and optimization of novel small molecules for therapeutic targets.

Value Proposition: 

The pharmaceutical industry has largely stopped exploring conventional natural products. Natural structures are typically difficult to source, difficult to identify, difficult to analog and difficult to manufacture. However, Nature is still the most efficient supplier of long lasting healthcare ingredients. Evolva´s Watchmaker® technology creates new combinations of synthetic structured products leading to new compounds that interact with the most productive functionalities of natural products. By mixing millions of genes from multiple species such as sponges, humans & plants, Watchmaker® creates long lasting solutions for patients with lifelong conditions.

Evolva is listed on the Swiss Stock Exchange as Evolva Holding SA.

 

www.evolvabio.comNeil Goldsmith (CEO), Prof. Dr. Erich Schlick (CoB)

Kaleido Technology

Kaleido shares was acquired by AAC Acoustic in 2011

Technology: 

Kaleido Technology is a manufacturer of integrated micro-optical components and sub-systems for applications in telecom, sensor and material processing. The solution enables the creation of free form aspheric mirrors and lenses with unprecedented properties when it comes to form accuracy, component size, and geometry.

Wecapack

Wecapack exited through management buy-out in 2010

Swantec

Swantech exited through management buy-out in 2008

TagAway Devices

Health care

Technology: 

TagAway Devices ApS has granted an exclusive license to a large international consumer health care company for its patented technology.

 

Carsten Fredsbo (CEO)

Virogates

Virogates exited through management buy-out in 2007

Image Metrology

Image Metrology exited through management buy-out in 2007

Orthometer

Orthometer exited through UK investor buy-out in 2004